Biosig Technologies, Inc. (NASDAQ:STEX – Get Free Report) Chairman Morgan Lee Lekstrom bought 34,000 shares of the stock in a transaction on Thursday, May 28th. The shares were acquired at an average cost of $1.47 per share, for a total transaction of $49,980.00. Following the purchase, the chairman owned 309,000 shares in the company, valued at $454,230. The trade was a 12.36% increase in their ownership of the stock. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available at this link.
Morgan Lee Lekstrom also recently made the following trade(s):
- On Thursday, May 21st, Morgan Lee Lekstrom bought 147,000 shares of Biosig Technologies stock. The shares were acquired at an average cost of $1.04 per share, for a total transaction of $152,880.00.
- On Tuesday, April 14th, Morgan Lee Lekstrom sold 12,759 shares of Biosig Technologies stock. The stock was sold at an average price of $1.07, for a total transaction of $13,652.13.
Biosig Technologies Stock Performance
STEX traded up $0.03 on Thursday, hitting $1.54. 1,870,279 shares of the company’s stock were exchanged, compared to its average volume of 1,907,106. Biosig Technologies, Inc. has a fifty-two week low of $0.70 and a fifty-two week high of $14.11. The firm’s 50-day simple moving average is $1.14. The company has a market capitalization of $279.07 million, a PE ratio of -0.16 and a beta of 1.58.
Analysts Set New Price Targets
STEX has been the topic of several analyst reports. Wall Street Zen lowered Biosig Technologies from a “hold” rating to a “strong sell” rating in a report on Sunday, April 5th. Needham & Company LLC reduced their price target on Biosig Technologies from $9.00 to $8.00 and set a “buy” rating on the stock in a report on Thursday, May 21st. Finally, Weiss Ratings upgraded Biosig Technologies from a “sell (e+)” rating to a “sell (d-)” rating in a report on Friday, May 1st. One analyst has rated the stock with a Buy rating and one has assigned a Sell rating to the company. According to data from MarketBeat.com, Biosig Technologies currently has an average rating of “Hold” and an average price target of $8.00.
Read Our Latest Report on Biosig Technologies
About Biosig Technologies
Biosig Technologies (NASDAQ:STEX) is a medical technology company focused on developing advanced signal acquisition and processing solutions for cardiac electrophysiology. The company’s work centers on improving the clarity and interpretability of intracardiac signals captured during electrophysiology procedures, with the goal of helping clinicians identify arrhythmogenic substrates and make more informed procedural decisions.
Its primary offering is a signal-processing platform that combines proprietary hardware and software to amplify, filter and display intracardiac electrical activity with reduced noise and distortion.
Read More
- Five stocks we like better than Biosig Technologies
- 3 Stocks Rallying on Micron’s Price Boost: Substance or Hype?
- Snowflake and the Snowballing Impact of its AI Flywheel
- AI’s Biggest Bottleneck Could Make These 2 Stocks Soar
- These 3 Beaten-Down Stocks Just Saw $25 Million in Insider Buying
Receive News & Ratings for Biosig Technologies Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Biosig Technologies and related companies with MarketBeat.com's FREE daily email newsletter.
